Biocon Sdn. Bhd. Enters Malaysia Book of Records as the First & the Largest Integrated Insulin Manufacturing Facility
  • Fri, 05-Aug-2022
  • Posted by: Biocon Biologics
No Comments

Biocon Q1FY23 Revenue at Rs 2,217 Cr, Up 23%; Net Profit at Rs 144 Cr, Up 71%; Core EBITDA at Rs 660 Cr Up 25%
  • Wed, 27-Jul-2022
  • Posted by: Biocon Biologics
No Comments

Biocon Biologics Receives EU GMP Certification for Its New Biologics Manufacturing Facility in Bengaluru
  • Tue, 05-Jul-2022
  • Posted by: Biocon Biologics
No Comments

Biocon Biologics issues a statement in response to the media reports related to bribery allegations
  • Tue, 21-Jun-2022
  • Posted by: Biocon Biologics
No Comments

Biocon Biologics Denies Bribery Allegations
  • Tue, 21-Jun-2022
  • Posted by: Biocon Biologics
No Comments

University of Glasgow officially Opens Mazumdar-Shaw Advance Research Centre
  • Thu, 09-Jun-2022
  • Posted by: Biocon Biologics
No Comments

Biocon Biologics and Viatris Launch Abevmy® (bBevacizumab), Their Third Oncology Biosimilar, in Canada
  • Thu, 19-May-2022
  • Posted by: Biocon Biologics
No Comments

Biocon Q4FY22 Revenue at Rs 2,476 Cr, Up 21%; Core EBITDA at Rs 815 Cr, Up 37% ; PBT(before Exceptional Items) at Rs 384 Cr, Up 9%
  • Thu, 28-Apr-2022
  • Posted by: Biocon Biologics
No Comments

Biocon Biologics’ Insugen® Awarded a Three-Year Contract by Ministry of Health, Malaysia
  • Tue, 26-Apr-2022
  • Posted by: Biocon Biologics
No Comments

Biocon Biologics’ Partner Receives Positive EU CHMP Opinion for Biosimilar Human Insulin for IV Infusion
  • Fri, 01-Apr-2022
  • Posted by: Biocon Biologics
No Comments
Report adverse event/ side effects and/or product complaints for Biocon Biologics products.

* Safe Harbour | Privacy Policy | Terms of Use © 2023, Biocon Biologics Limited (a Subsidiary of Biocon Limited). All Rights Reserved
Share